← Back to patent-cliff list
Rilzabrutinib
Tier C — Watch / tradeRilzabrutinib
Principia Biopharma Inc
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BTK
Brand：Wayrilz
Indications (approved)：Immune thrombocytopenic purpura
Regional status
US
Approved
2025-08-29
EU
Approved
2025-12-22
China
Approved
2026-09-02
Japan
Approved
2026-06-23
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Rilzabrutinib?
Approved indications include: Immune thrombocytopenic purpura.
When does the Rilzabrutinib patent expire?
No public expiry year is available for Rilzabrutinib yet; this page updates once verified.
How do I get a quote for Rilzabrutinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01